09:54 EST Kyverna Therapeutics (KYTX) Inc trading halted, volatility trading pause
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Reports Positive Phase 2 Trial Results
- Kyverna Therapeutics Reports Positive Phase 2 Trial Results
- Kyverna Therapeutics announces topline data from registrational KYSA-8 trial
- Kyverna Therapeutics price target raised to $25 from $20 at Morgan Stanley
- Kyverna Therapeutics, Inc.: A Promising Market Position with KYV-101’s Potential as the First FDA-Approved CAR-T Therapy for Autoimmune Diseases